Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences

Rhea-AI Summary

Werewolf Therapeutics (Nasdaq: HOWL) will present preclinical data on its IL-12 INDUKINE molecule, mWTX-330, at the Society for Immunotherapy of Cancer's 37th Annual Meeting on November 11, 2022. This research focuses on tumor-infiltrating lymphocytes and the tumor microenvironment in murine models. Additionally, the management team is set to engage in several investor conferences, including the Jefferies London Healthcare Conference on November 15 and the Piper Sandler Conference on November 29. These events aim to enhance investor relations and share insights into Werewolf's innovative cancer therapies.

Positive

• Upcoming presentation of preclinical data at a significant oncology conference.
• Participation in multiple investor conferences, enhancing visibility and investor engagement.
• Focus on innovative therapeutics leveraging proprietary PREDATOR™ platform to stimulate cancer immunity.

Negative

• None.

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced upcoming oncology research and investor community events in which Werewolf scientists and management will participate.

This week, Werewolf will present preclinical data at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 8-12, 2022, in Boston, and virtually. The detailed data will be presented in a poster presentation titled, “mWTX-330, an IL-12 INDUKINE™ molecule, Selectively Activates Tumor Infiltrating Lymphocytes and Reprograms the Tumor Microenvironment in Murine Syngeneic Tumor Models” (Abstract #1096) on Friday, November 11 at 11:55 am - 1:25 pm EST, in Hall C. The full abstract is now available for review on the SITC annual meeting website.

Werewolf’s management team will also participate in the following upcoming investor conferences:

Jefferies London Healthcare Conference
Date/Time: Tuesday, November 15 at 5:35 pm GMT (12:35 pm EST)
Location: London, UK
Management will participate in a fireside chat and be available for one-on-one meetings.

Piper Sandler 34^th Annual Healthcare Conference
Date/Time: Tuesday, November 29 at 10:10 am EST
Location: New York, NY
Management will present and be available for one-on-one meetings.

5^th Annual Evercore ISI HealthCONx Conference
Date/Time: Tuesday, November 29 at 9:15 am EST
Location: Virtual
Management will participate in a fireside chat and be available for one-on-one meetings.

BofA Securities 2022 Biotech SMID Cap Conference
Date/Time: Thursday, December 8 at 2:15 pm EST
Location: Boston, MA
Management will participate in a fireside chat and be available for one-on-one meetings.

Links to the live webcasts for the Jefferies, Evercore ISI and BofA Securities conferences will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following each presentation.

About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. To learn more visit www.werewolftx.com. 

Investor Contact:
Josh Rappaport
Stern IR
212.362.1200
Josh.Rappaport@sternir.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com

Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

FAQ

What data will Werewolf Therapeutics present at the SITC meeting?

Werewolf Therapeutics will present preclinical data on mWTX-330, an IL-12 INDUKINE molecule, focusing on its effects on tumor-infiltrating lymphocytes.

When is Werewolf Therapeutics presenting at the SITC conference?

The presentation is scheduled for November 11, 2022, from 11:55 am to 1:25 pm EST.

Which investor conferences will Werewolf Therapeutics attend?

Werewolf will participate in the Jefferies London Healthcare Conference on November 15, the Piper Sandler Conference on November 29, and others.

What is the significance of Werewolf's INDUKINE molecules?

INDUKINE molecules are designed to activate selectively in the tumor microenvironment, potentially improving cancer treatment outcomes.